These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 35698070)

  • 1. Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience.
    Silvestro M; Tessitore A; Orologio I; De Micco R; Tartaglione L; Trojsi F; Tedeschi G; Russo A
    J Headache Pain; 2022 Jun; 23(1):69. PubMed ID: 35698070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
    Russo A; Silvestro M; Scotto di Clemente F; Trojsi F; Bisecco A; Bonavita S; Tessitore A; Tedeschi G
    J Headache Pain; 2020 Jun; 21(1):69. PubMed ID: 32517693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
    Ailani J; Andrews JS; Rettiganti M; Nicholson RA
    J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study.
    Viudez-Martínez A; Pascual-Carrasco A; Beltrán-Blasco I; Hernandez-Lorido R; F Ruiz de Apodaca R
    J Clin Pharm Ther; 2022 Jun; 47(6):814-823. PubMed ID: 35212025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
    Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
    J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life experiences with galcanezumab and predictors for treatment response in Turkey.
    Yalinay Dikmen P; Baykan B; Uludüz D; Özge A; Ilgaz Aydınlar E; Polat B; Karlı N; Tepe N; Çelebisoy N; Ergin Toktaş H; Niflioğlu B; Karacı R; Mayda Domaç F; Uludüz E; Erdogan Soyukibar T; Öksüz N; Ertaş M
    BMC Neurol; 2023 Nov; 23(1):418. PubMed ID: 37996793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
    Camporeale A; Kudrow D; Sides R; Wang S; Van Dycke A; Selzler KJ; Stauffer VL
    BMC Neurol; 2018 Nov; 18(1):188. PubMed ID: 30413151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study.
    Okonkwo R; Tockhorn-Heidenreich A; Stroud C; Paget MA; Matharu MS; Tassorelli C
    J Headache Pain; 2021 Sep; 22(1):113. PubMed ID: 34592919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
    Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
    Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
    J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
    [No Abstract]   [Full Text] [Related]  

  • 16. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures.
    Schwedt TJ; Kuruppu DK; Dong Y; Standley K; Yunes-Medina L; Pearlman E
    J Headache Pain; 2021 Mar; 22(1):15. PubMed ID: 33765912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
    Reuter U; Lucas C; Dolezil D; Hand AL; Port MD; Nichols RM; Stroud C; Tockhorn-Heidenreich A; Detke HC
    Adv Ther; 2021 Nov; 38(11):5465-5483. PubMed ID: 34542830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial.
    Schwedt TJ; Myers Oakes TM; Martinez JM; Vargas BB; Pandey H; Pearlman EM; Richardson DR; Varnado OJ; Cobas Meyer M; Goadsby PJ
    Neurol Ther; 2024 Feb; 13(1):85-105. PubMed ID: 37948006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
    Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Pierangeli G; Lovati C; Aguggia M; d'Onofrio F; Doretti A; Di Fiore P; Finocchi C; Rao R; Bono F; Ranieri A; Albanese M; Cevoli S; Barbanti P;
    J Headache Pain; 2021 May; 22(1):35. PubMed ID: 33941080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.